Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609140 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
NCT01609140 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 248 participants.
The verdict
NCT01609140, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and cholesterol lowering effects of MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a high risk of cardiovascular events and LDL-c levels well above goal.
Interventions
- DRUG MPSK3169A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01609140
The ClinicalTrials.gov registry entry for NCT01609140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MPSK3169A is the first listed.
NCT01609140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01609140 about?
NCT01609140 is a clinical study titled "A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease". The purpose of this study is to evaluate the safety and cholesterol lowering effects of MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a high risk of cardiovascular events and LDL-c levels well above goal.
What is the current status of trial NCT01609140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2012-05. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01609140?
The interventions under investigation include: MPSK3169A (DRUG).
Who is sponsoring clinical trial NCT01609140?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.